(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 22 Jan 2024
Net transaction value: +$39,998,163
SEC form: 4
Accepted by SEC: 24 Jan 2024, 18:55:26 UTC
Prior SEC filing: 13 Sep 2023
Source filing: View source filing
Reporting owner signature: LEI MENG, /s/ Adam Veness, as attorney-in-fact for Lei Meng

Key filing fact

Lei Meng filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 24 Jan 2024.

Key facts

This page summarizes Lei Meng's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jan 2024, 18:55.

Change

Previous filing in this sequence was filed on 13 Sep 2023.
Current net transaction value: +$39,998,163.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Award

Transaction value: $18,000,000
Shares: +1,500,000
Change %: +123%
Price: $12.00
Shares after: 2,717,554
Date: 22 Jan 2024
Ownership: See footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Pre-Funded Warrants (Right to Buy)

Award

Transaction value: $21,998,163
Shares: +1,833,333
Change %
Price: $12.00
Shares after: 1,833,333
Date: 22 Jan 2024
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,833,333
Exercise price: $0.001000
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Consists of an aggregate of 1,500,000 shares of common stock purchased by clients of Avidity Partners Management LP from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Footnote F2

The reported securities are held by clients of Avidity Partners Management LP and may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC. Lei Meng, an employee of Avidity Partners Management LP, is a director of the Issuer. Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Mr. Witzke and Mr. Gregory may be considered directors by deputization due to their affiliation with Ms. Meng. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its, his or her pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Footnote F3

Consists of Pre-Funded Warrants to purchase up to an aggregate of 1,833,333 shares of common stock purchased by clients of Avidity Partners Management LP from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Exchange Act.

Footnote F4

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.